Abstract
While the use of resveratrol provides an intriguing therapeutic option that addresses many of the pathogenic processes involved in PKD progression, its improper use can have potential adverse consequences. For instance, via overactivation of SIRT1, it may enhance formation and enlargement of cysts and at high doses it may intensify inflammation and accelerate progression of renal disease.